(Q36972489)

17 August 2017

1 reference

title

Increasing protection after tamoxifen: insights from the extended adjuvant aromatase inhibitor trials (English)

1 reference

17 August 2017

1 reference

Carsten Rose

1

1 reference

17 August 2017

publication date

16 October 2007

1 reference

Journal of Cancer Research and Clinical Oncology

17 August 2017

published in

1 reference

17 August 2017

volume

134

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

7-17

1 reference

The pharmacology and clinical uses of tamoxifen

17 August 2017

cites work

1 reference

12 December 2020

Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.

1 reference

12 December 2020

Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective

1 reference

12 December 2020

Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer

1 reference

12 December 2020

Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer

1 reference

12 December 2020

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

1 reference

12 December 2020

Are all aromatase inhibitors the same? A review of the current evidence

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial

1 reference

12 December 2020

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer

1 reference

12 December 2020

Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example

1 reference

12 December 2020

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

1 reference

12 December 2020

Skeletal health in postmenopausal survivors of early breast cancer.

1 reference

12 December 2020

Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women

1 reference

12 December 2020

Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial

1 reference

12 December 2020

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

12 December 2020

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

12 December 2020

Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy

1 reference

12 December 2020

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

12 December 2020

Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen

1 reference

12 December 2020

Breast cancer prevention—clinical trials strategies involving aromatase inhibitors

1 reference

12 December 2020

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Systematic overview of cost-utility assessments in oncology

1 reference

12 December 2020

Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial

1 reference

12 December 2020

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

1 reference

12 December 2020

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

12 December 2020

The causes and treatment of bone loss associated with carcinoma of the breast

1 reference

12 December 2020

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

12 December 2020

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

12 December 2020

Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen

1 reference

12 December 2020

10.1007/S00432-007-0324-8

Identifiers

DOI

1 reference

release_qyl5ytfikzcshfmlmreao6e33a

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qyl5ytfikzcshfmlmreao6e33a

24 November 2022

mapped directly with Wikidata item

1 reference